Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on February 5, 2013, to report its financial results for the fiscal year ended December 31, 2012. The filing includes unaudited consolidated balance sheets, statements of operations, and cash flows.
Key Financial Metrics
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $26.0 million | $33.9 million |
| Gross Profit | $0.9 million | $13.0 million |
| Gross Margin | 3.6% | 38.5% |
| Operating Expenses | $95.3 million | $122.8 million |
| Cash and Investments | $100.6 million | $177.4 million |
| Instrument Backlog | $2.9 million (5 systems) | $11.0 million (16 systems) |
The filing does not provide a specific net loss figure or detailed debt obligations, though it notes cash usage of $76.8 million for the year.
Material Changes
- Revenue Decline: Revenue decreased by approximately 23% year-over-year.
- Margin Compression: Gross margin dropped significantly from 38.5% to 3.6%. The 2011 margin was artificially inflated by the expensing of instrument components prior to the commercial launch in Q2 2011.
- Backlog Reduction: Instrument revenue backlog fell from $11.0 million to $2.9 million, representing a reduction from 16 systems to 5 systems.
- Cash Burn: Cash and investments decreased by $76.8 million, reflecting significant operating cash usage.
Outlook and Management Commentary
- Revenue Guidance: The company expects total 2013 revenue to exceed 2012 levels, though Q1 2013 revenue is expected to decrease sequentially from Q4 2012.
- Margin Outlook: Overall gross margins are expected to remain in the single digits for 2013.
- Expense Guidance: Operating expenses are projected to be $22 million or less per quarter in 2013.
- Liquidity: Cash usage in 2013 is expected to decrease compared to 2012, excluding the impact of potential debt or equity financing.
- Risks: The filing contains forward-looking statements subject to significant risks and uncertainties, including those detailed in the most recent Form 10-Q.
Investor Verification Checklist
- Verify the specific net loss amount for 2012 in the referenced Exhibit 99.2 (Consolidated Statements of Operations).
- Confirm the exact cash burn rate per quarter for 2012 to assess the runway provided by the $100.6 million cash balance.
- Review the details of the 5 systems in the current backlog to understand the timing of expected revenue recognition.
- Examine the breakdown of operating expenses to validate the feasibility of the $22 million per quarter guidance.